Results 161 to 168 of about 1,211,683 (168)

The universal zero markup drug policy and gastric cancer hospitalization expenses: an analysis of trends and influencing factors in Shanghai from 2014 to 2021. [PDF]

BMC Health Serv Res
Gu Y, Hao J, He D, Sun H, Cui X, Tian W, Zhang Y, Jin C, Wang H.   +8 more
europepmc   +1 more source

Tremelimumab plus durvalumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: a cost-effectiveness analysis from the US payer perspective. [PDF]

BMJ Open
Cheng S, Li B, Tang L, Liu S, Xiao J.
europepmc   +1 more source

Number needed to treat and associated cost analysis of zanubrutinib vs ibrutinib in chronic lymphocytic leukemia. [PDF]

J Manag Care Spec Pharm
Chanan-Khan A, Hanna K, Xue M, Massoudi M, Balk M, Gani R, Piran HZ, Yang K.   +7 more
europepmc   +1 more source

INSTIs-centered antiviral regimens for first-line treatment of HIV/AIDS: a network meta-analysis and cost-effectiveness analysis. [PDF]

BMC Infect Dis
Yang J, Zhao X, Li F.
europepmc   +1 more source

Substantial variation among Medicare beneficiaries in the impact from 2025 Part D out of pocket spending caps. [PDF]

Health Aff Sch
Lederman DM, Olssen AL, Pauly MV.
europepmc   +1 more source

The need to consider market access for pharmaceutical investment decisions: a primer. [PDF]

J Comp Eff Res
Ramagopalan SV, Bacon C, Walker M, Ryan ML.   +3 more
europepmc   +1 more source